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Objective: Neurofilaments in CSF are promising biomarkers which might help in the
diagnosis of motor neuron disease (MND). We aim to assess the diagnostic value of
neurofilaments in CSF for MND.
Methods: Pubmed, Emabase, and Web of Science were searched for relevant studies
systematically. Articles in English that evaluated the utility of neurofilaments in CSF
in the diagnosis of MND were included. Data were extracted by two independent
investigators. Diagnostic indexes for neurofilament light chain (NFL) and phosphorylated
neurofilament heavy chain (pNFH) were calculated separately. Stata 12.0 software with
a bivariate mixed-effects model was used to summarize the diagnostic indexes from
eligible studies.
Results: Five studies on NFL and eight studies on pNFH met inclusion criteria. For
NFL, the pooled sensitivity and specificity were 81% (95% confidence interval [CI], 72–
88%) and 85% (95% CI, 76–91%), respectively; the positive likelihood ratio (PLR) and
negative likelihood ratio (NLR) were 5.5 (95% CI, 3.1–9.8) and 0.22 (95% CI, 0.14–0.35),
respectively; the summary diagnostic odds ratio (DOR) was 25 (95% CI, 9–70), and the
area under summary receiver operator characteristic curve (AUC) was 0.90 (95% CI,
0.87–0.92). For pNFH, the pooled sensitivity, specificity, PLR and NLR were 85% (95%
CI, 80–88%), 85% (95% CI, 77–90%), 5.5 (95% CI, 3.6–8.4), and 0.18 (95% CI, 0.13–
0.25), respectively; the DOR was 30 (95% CI, 16–58), and the AUC was 0.91 (95% CI,
0.88–0.93).
Conclusion: Neurofilaments in CSF have a high value in the diagnosis of MND, though
the optimal cutoff value remains to be further investigated.
Keywords: motor neuron disease, amyotrophic lateral sclerosis, CSF biomarkers, neurofilaments, diagnostic
value, meta-analysis
INTRODUCTION
Motor neuron diseases (MND) are a group of progressive neurodegenerative disorders
characterized by motor neuron loss in the motor cortex, brainstem, and spinal cord. The most
common form is amyotrophic lateral sclerosis (ALS), which affects both upper motor neuron
(UMN) and lower motor neuron (LMN). Early diagnosis of ALS remains to be a challenge
worldwide. Population studies have shown that the average diagnosis latency is about 12 months
(Zoccolella et al., 2006), and patients who fulfill the revised El Escorial criteria for clinically
definite ALS are usually in the advanced stage of the disease (Turner and Talbot, 2013). Validated
biomarkers that can facilitate earlier diagnosis of ALS are urgently needed in order to enable
disease-modifying drugs to be administered at an earlier stage.
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Neurofilaments are the most abundant neuronal cytoskeletal
proteins and are essential to the structural integrity of neurons.
Neurofilament subunits, mainly neurofilament light chain (NFL)
and phosphorylated neurofilament heavy chain (pNFH), are
actively involved in the pathogenesis of axonal injury and
degeneration both as causative agents and progression markers
for neurological diseases (Petzold, 2005). ALS is characterized
by loss of large axons with abundant neurofilaments, and
perikaryal accumulation of phosphorylated neurofilaments has
been found to occur in ALS (Manetto et al., 1988). Several
studies and meta-analysis have showed that concentrations of
NFL and pNFH in CSF are significantly increased in patients
with ALS (Xu et al., 2016), suggesting that they might be
promising neurochemical diagnostic biomarkers for ALS. To
fully understand the diagnostic performance of NFL and pNFH
for MND, we performed the present meta-analysis to summarize
their diagnostic indexes.
MATERIALS AND METHODS
Inclusion of Studies
Pubmed, Embase databases and Web of Science were searched
for studies published up to October 31st, 2016 that reported
neurofilament concentrations in CSF in patients with MND.
Search terms included (‘motor neuron disease’ or ‘MND’
or ‘amyotrophic lateral sclerosis’ or ‘ALS’) AND (‘NFL’ or
‘NEFL’ or ‘NFH’ or ‘NEFH’ or ‘pNFH’ or ‘neurofilament’
or ‘neurofilaments’ or ‘light chain’ or ‘heavy chain’) AND
(‘cerebrospinal fluid’ or ‘cerebrospinal fluids’ or ‘CSF’ or
‘biomarker’ or ‘biomarkers’ or ‘biological marker’ or ‘biological
markers’). Both text word and MeSH subject headings were
used. Language was confined to English, and publication
type of review, case reports and letter was excluded in the
advanced search. The search strategy was supplemented by
inspecting the reference lists of included articles. The studies
were considered for inclusion if they (1) evaluated the utility
of neurofilament concentrations in CSF for the diagnosis of
MND; (2) enrolled healthy controls or patients with neurological
disorders other than MND as controls; (3) provide enough data
to construct a 2 × 2 table for the diagnostic accuracy. Studies
were excluded if they were in line with the following criteria:
(1) there was no control group; (2) measured neurofilament
concentrations in biological samples other than CSF, including
plasma, serum, spinal cords, or brain tissue from biopsy;
(3) used non-quantitative methods such as western blot, or
assessed the diagnostic accuracy of anti-neurofilament antibodies
for MND; (4) had overlapped sample or the sample size
<10; (5) could not provide valid data after contacting the
authors.
FIGURE 1 | The flow chart of the literature search in the meta-analysis.
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FIGURE 2 | Methodological quality summary.
Data Extraction and Quality Assessment
For each included study, the following data were extracted
by two investigators independently using a standard form:
country of origin, number of centers, number of cases, patient
type, ALS diagnostic criteria, control type, study design, testing
method, mean or median value of neurofilaments, cutoff value,
and diagnostic indexes. The Quality Assessment of Diagnostic
Accuracy Studies-2 (QUADAS-2) tool was used to assess the
quality of included studies and their risk of bias (Whiting
et al., 2011). The figure of risk of bias and applicability
concerns summary was produced using Revman 5.3 software.
Any conflicts were resolved by a third party after discussion of
each item.
Data Analysis
We used STATA software (version 12.0, Stata Corporation,
93 College Station, TX, USA) to perform the meta-analysis.
A bivariate mixed-effects model was used to analyze the
estimates of sensitivity, specificity, positive likelihood ratio
(PLR), negative likelihood ratio (NLR), and diagnostic odds
ratio (DOR) with 95% confidence interval (CI). The summary
receiver operator characteristic (SROC) curve was constructed
and the area under the SROC curve (AUC) was calculated
to evaluate the overall performance of CSF neurofilaments in
MND patients. P < 0.1 for Q-test or I2 ≥ 50% for I2 statistics
indicated substantial heterogeneity, in which case heterogeneity
test would be performed. The leave-one-out sensitivity analyses
were conducted to test the replicability of the results, which
consists of repeating the main analysis by removing each study
one at a time to recalculate the stability of the remaining studies.
Subgroup analyses for pNFH according to study design, testing
method, cutoff value, patient type, diagnosis criteria, control type,
and population were also carried out. Deeks’ funnel plots were
used to test for the potential presence of publication bias, and
P < 0.05 was considered statistically significant.
RESULTS
Search Results and Characteristics of
Included Studies
A total of 344 articles were identified. After removal of duplicate
entries, 243 articles remained and then were screened by title
and abstract. As a result, 28 full-text articles were assessed for
eligibility, of which three had no control group (Boylan et al.,
2013; Tortelli et al., 2015; Weydt et al., 2016), five investigated
neurofilament levels in other biological samples (Troost et al.,
1992; Strong et al., 2001; Mendonca et al., 2005; Puentes
et al., 2014; McCombe et al., 2015), one utilized western blot
(Mendonca et al., 2011) and one measured anti-neurofilament
antibodies (Fialova et al., 2010), two had overlapping data
sets (Brettschneider et al., 2006; Goncalves et al., 2015) and
two had a sample size <10 (Norgren et al., 2003; Petzold
et al., 2003), and three did not provide sufficient data to
allow construct a 2 × 2 table (Kuhle et al., 2010; Gaiottino
et al., 2013; Lehnert et al., 2014), one was a systematic review
and meta-analysis (Xu et al., 2016). Finally, 10 articles were
included in the meta-analysis, of which two reported data on
NFL only (Tortelli et al., 2012; Lu et al., 2015), five reported
on pNFH only (Ganesalingam et al., 2011, 2013; Chen et al.,
2016; Goncalves et al., 2016; Li et al., 2016) and three reported
both (Reijn et al., 2009; Steinacker et al., 2015; Oeckl et al.,
2016). A flow chart of publication selection is presented in
Figure 1. Of note, one study that focused on multicenter
validation of CSF neurofilaments as diagnostic biomarkers for
ALS enrolled participants from 15 centers across Europe and
America (Oeckl et al., 2016), part of which might overlapped
with other four studies (Ganesalingam et al., 2013; Lu et al.,
2015; Steinacker et al., 2015; Goncalves et al., 2016). However,
the multicenter study only recruited five ALS patients and five
controls from each center; therefore, we reckoned that the
multiple publication bias, if existed, could be ignored in view of
the relative large total sample size. The basic characteristics of
each study are shown in Table 1. More details please refer to the
Supplementary Data Sheet 1.
Quality Assessment
Quality assessment results based on QUADAS-2 are shown in
Figure 2. Concerning the domain of patient selection, only
three studies were cross-sectional (Tortelli et al., 2012; Lu
et al., 2015; Chen et al., 2016), while other seven studies
were case-control designed; only one study reported that their
patients were enrolled consecutively, and two studies reported
their controls were age- and sex-matched to cases (Tortelli
et al., 2012; Chen et al., 2016), and two studies reported the
controls were only age-matched to the cases (Ganesalingam
et al., 2011; Li et al., 2016), while other studies did not describe
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FIGURE 3 | Forest plots showing the sensitivity and specificity of NFL in the diagnosis of MND.
these information explicitly; four studies used healthy controls
who “came from the community,” “were typically spouses and
friends of patients,” “were initially presented with neurological
symptoms and underwent lumber puncture as a part of the
diagnostic examinations” but turned out to be without any
neurological disease, or were not specified. (Ganesalingam
et al., 2011; Lu et al., 2015; Li et al., 2016; Oeckl et al.,
2016); neurological controls usually included the following:
ALS mimics, other neurodegenerative diseases, inflammatory
conditions, and other neurological diseases. More information
about the neurological controls in each included study please
refer to the Supplementary Data Sheet 1. As for the index test,
all studies selected the test threshold to optimize sensitivity and
specificity instead of using a pre-specified threshold. Two studies
had a high risk of the flow and timing item, since some of the
patients enrolled in the studies were not included in the final
analysis (Reijn et al., 2009; Oeckl et al., 2016). One study did not
report explicitly its diagnostic criteria for ALS, therefore its risk of
reference standard remains unclear (Ganesalingam et al., 2013).
Diagnostic Accuracy
For NFL, the pooled sensitivity, specificity, PLR and NLR were
81% (95% CI, 72–88%), 85% (95% CI, 76–91%), 5.5 (95% CI,
3.1–9.8), and 0.22 (95% CI, 0.14–0.35), respectively; the summary
DOR was 25 (95% CI, 9–70), and the AUC was 0.90 (95% CI,
0.87–0.92) (Figures 3 and 4A).
For pNFH, the pooled sensitivity, specificity, PLR and NLR
were 85% (95% CI, 80–88%), 85% (95% CI, 77–90%), 5.5 (95% CI,
3.6–8.4), and 0.18 (95% CI, 0.13–0.25), respectively; the summary
DOR was 30 (95% CI, 16–58), and the AUC was 0.91 (95% CI,
0.88–0.93) (Figures 4B and 5).
Exploration of Heterogeneity and
Publication Bias
A bivariate mixed-effects model was used in this meta-analysis.
No significant heterogeneity was found among studies on
NFL (P = 0.493, I2 = 0), and moderate heterogeneity was
detected among studies on pNFH (P = 0.077, I2 = 47).
Sensitivity analyses indicated that results of the main meta-
analysis were stable for NFL (Table 2). However, in the leave-one-
out analysis for pNFH, the moderate heterogeneity disappeared
when Ganesalingam et al. (2011; I2 = 0) or Oeckl et al. (2016;
I2 = 8) was removed, suggesting they might be the sources of
heterogeneity. In the subgroup analyses for pNFH, when studies
were confined to those used neurological controls only, the
heterogeneity also disappeared (Table 3). The results of Deeks’
test did not reveal significant publication bias in this study
(Figure 6).
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FIGURE 4 | Summary receiver operator characteristic of the accuracy of NFL (A) and pNFH (B) in the diagnosis of MND.
FIGURE 5 | Forest plots showing the sensitivity and specificity of pNFH in the diagnosis of MND.
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TABLE 2 | Results of sensitivity analyses.
Variables P for
Q-test
I2
statistics
Sensitivity
(95% CI)
Specificity
(95% CI)
PLR
(95% CI)
NLR
(95% CI)
DOR
(95% CI)
AUC
(95% CI)
Sensitivity analysis for NFL
Oeckl et al., 2016 0.496 0 0.82 (0.69–0.91) 0.86 (0.73–0.93) 5.7 (2.6–12.7) 0.21 (0.10–0.41) 28 (6–119) 0.91 (0.88–0.93)
Lu et al., 2015 0.492 0 0.79 (0.74–0.83) 0.83 (0.76–0.88) 4.6 (3.2–6.5) 0.26 (0.21–0.32) 18 (11–30) 0.83 (0.79–0.86)
Steinacker et al., 2015 0.489 0 0.83 (0.71–0.91) 0.84 (0.71–0.92) 5.3 (2.5–11.4) 0.20 (0.10–0.39) 26 (7–101) 0.90 (0.88–0.93)
Tortelli et al., 2012 0.426 0 0.84 (0.71–0.91) 0.87 (0.80–0.92) 6.5 (3.7–11.5) 0.19 (0.10–0.36) 35 (11–109) 0.92 (0.89–0.94)
Reijn et al., 2009 0.497 0 0.83 (0.71–0.90) 0.87 (0.76–0.93) 6.2 (3.0–12.9) 0.20 (0.10–0.37) 32 (8–118) 0.92 (0.89–0.94)
Sensitivity analysis for pNFH
Li et al., 2016 0.065 51 0.85 (0.79–0.89) 0.86 (0.79–0.91) 6.1 (3.8–9.6) 0.18 (0.12–0.25) 35 (17–70) 0.92 (0.89–0.94)
Chen et al., 2016 0.041 60 0.83 (0.79–0.87) 0.85 (0.76–0.90) 5.4 (3.3–8.7) 0.20 (0.15–0.26) 28 (14–55) 0.89 (0.86–0.91)
Oeckl et al., 2016 0.361 0 0.86 (0.81–0.89) 0.82 (0.75–0.88) 4.9 (3.2–7.5) 0.17 (0.12–0.25) 28 (13–60) 0.91 (0.88–0.93)
Goncalves et al., 2016 0.064 51 0.85 (0.81–0.89) 0.86 (0.80–0.91) 6.3 (4.2–9.4) 0.17 (0.12–0.23) 37 (21–67) 0.92 (0.89–0.94)
Steinacker et al., 2015 0.112 33 0.85 (0.78–0.90) 0.86 (0.78–0.91) 6.1 (3.7–9.8) 0.18 (0.12–0.26) 34 (16–73) 0.92 (0.89–0.94)
Ganesalingam et al., 2013 0.032 64 0.83 (0.79–0.87) 0.84 (0.75–0.90) 5.3 (3.3–8.7) 0.20 (0.15–0.26) 27 (14–53) 0.88 (0.85–0.91)
Ganesalingam et al., 2011 0.169 8 0.84 (0.78–0.89) 0.83 (0.75–0.88) 4.9 (3.32–7.2) 0.19 (0.13–0.27) 26 (13–49) 0.90 (0.87–0.93)
Reijn et al., 2009 0.091 41 0.85 (0.81–0.89) 0.84 (0.76–0.90) 5.5 (3.4–8.7) 0.17 (0.13–0.24) 32 (16–65) 0.91 (0.88–0.93)
AUC, area under curve; DOR, diagnostic odd ratio; NFL, neurofilament light chain; NLR, negative likelihood ratio; PLR, positive likelihood ratio; pNFH, phosphorylated
neurofilament heavy chain.
TABLE 3 | Results of subgroup analyses for pNFH.
Variables P for Q-test I2 statistics Sensitivity
(95% CI)
Specificity
(95% CI)
PLR (95% CI) NLR (95% CI) DOR (95% CI) AUC (95% CI)
Case-control
studies
0.041 60 0.83 (0.79–0.87) 0.85 (0.76–0.90) 5.4 (3.3–8.7) 0.20 (0.15–0.26) 28 (14–55) 0.89 (0.86–0.91)
Cutoff <1000
pg/mL
0.032 64 0.83 (0.79–0.87) 0.84 (0.75–0.90) 5.3 (3.3–8.7) 0.20 (0.15–0.26) 27 (14–53) 0.88 (0.85–0.91)
ELISA method 0.091 41 0.85 (0.81–0.89) 0.84 (0.76–0.90) 5.5 (3.4–8.7) 0.17 (0.13–0.24) 32 (16–65) 0.91 (0.88–0.93)
ALS only 0.112 33 0.85 (0.78–0.90) 0.86 (0.78–0.91) 6.1 (3.7–9.8) 0.18 (0.12–0.26) 34 (16–73) 0.92 (0.89–0.94)
R-El Escorial
only
0.08 45 0.82 (0.79–0.86) 0.82 (0.74–0.89) 4.6 (4.0–7.0) 0.21 (0.17–0.26) 22 (13–36) 0.85 (0.82–0.88)
Europe and
America
0.04 60 0.83 (0.78–0.88) 0.86 (0.77–0.92) 6.0 (3.5–10.2) 0.19 (0.14–0.26) 31 (15–66) 0.90 (0.87–0.92)
NC only 0.465 0 0.86 (0.78–0.91) 0.81 (0.73–0.87) 4.5 (3.0–6.7) 0.18 (0.11–0.29) 25 (10–62) 0.90 (0.87–0.92)
ALS, amyotrophic lateral sclerosis; AUC, area under curve; DOR, diagnostic odd ratio; NC, neurological control; NLR, negative likelihood ratio; PLR, positive likelihood
ratio; pNFH, phosphorylated neurofilament heavy chain, R-El Escorial, revised El Escorial.
DISCUSSION
Neurofilament proteins are essential for maintaining normal
axonal caliber and conduction velocity. Elevated levels of NFL
and pNFH are reflections of ongoing destruction of axons,
as have been shown in MND and other neurodegenerative
diseases (Brettschneider et al., 2006). Our study provides a
comprehensive meta-analysis of the CSF neurofilaments as
diagnostic biomarkers in MND. A high AUC for both biomarkers
qualified them as discriminative markers for suspected MND, and
the results of sensitivity analyses demonstrated the overall results
were stable. However, negative results for these markers cannot
rule out MND diagnosis.
Though CSF NFL and pNFH concentrations have been
shown to be consistently increased in ALS patients, the cutoff
value for diagnosis among studies varies considerably, and the
pNFH measurement appears to be more robust than the NFL
assay (Li et al., 2016). For pNFH, its concentrations were
comparable among different centers and the inter-laboratory
variation of measurements was acceptable, partly because it
seems to be stable against preanalytical variables and is less
affected by blood contamination, repeated freeze-thaw cycles,
delayed processing, or storage temperature (Koel-Simmelink
et al., 2014). On the contrary, stability remains to be a particular
problem for NFL (Koel-Simmelink et al., 2011), which limits
its practicability and challenges it as a biomarker to be used
in clinical trials. Concerning the assay methods, besides the
purchasable ELISA methods, two studies (Reijn et al., 2009;
Tortelli et al., 2012) utilized independent specific enzyme
immunoassay for the detection of NFL (Norgren et al., 2003; Van
Geel et al., 2005), and one study used electrochemiluminescence
immunoassay (Lu et al., 2015). Beyond the preanalytical and
analytical aspects as reasons for neurofilament cutoff variability
among centers, effects of clinical differences also played an
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FIGURE 6 | The Deeks’ test of the diagnostic meta-analysis [(A) NFL and (B) pNFH].
important role, especially disease duration, rate of progress and
the neurological controls with a variety of syndromes. Studies
have shown that CSF pNFH levels are inversely correlated with
disease duration (Ganesalingam et al., 2013), while NFL levels
changed only minimally throughout most of the disease course
in ALS (Lu et al., 2015); CSF pNFH levels were higher in
patients with predominantly UMN involvement (Brettschneider
et al., 2006), while NFL levels did not differ between patients
with predominantly UMN involvement and patients with
predominantly LMN involvement (Tortelli et al., 2012); ALS-fast
tend to have higher CSF NFL and pNFH levels than ALS-slow
(Tortelli et al., 2012; Goncalves et al., 2015; Lu et al., 2015; Chen
et al., 2016).
The broad range of neurofilament values might accentuate its
general applicability in MND diagnosis. Thus, standardization
of the above-mentioned factors in combination with personnel
training and regular quality control are now recommended and
commonly accepted in order to give reproducible results
in different laboratories and to successfully implement
neurofilaments determination as diagnostic criteria for
ALS (Lehnert et al., 2014; Oeckl et al., 2016). In addition,
neurofilament measurements should be ideally undertaken as
close as to reported disease onset, when ALS is suspected or at
diagnosis.
An important concern for neurofilaments as diagnostic
biomarkers is the timing of their increase. Weydt et al. (2016)
found that asymptomatic individuals carrying an ALS mutation
did not show any trend toward increased levels of NFL and
pNFH, even when they were close to the assumed disease onset.
However, there was an increase in CSF neurofilament levels
between asymptomatic carriers and symptomatic ALS patients
and this increase might turn out to be a rather sudden event,
possibly reflecting the onset of irreversible structural damage
of motor neurons. Their results indicate that neurofilaments
are state markers closely related to the symptomatic phase.
Longitudinal studies are needed to help determine when the surge
in neurofilament levels occurs exactly in relation to the phenotype
conversion.
Despite the potential diagnostic accuracy of CSF
neurofilaments, serial lumbar punctures for longitudinal
neurofilaments monitoring are far less practical than blood
sampling, which makes blood-derived neurofilaments level
a more favorable surrogate marker for disease staging and
prognosis in ALS (Puentes et al., 2014; McCombe et al., 2015).
Three studies investigating the correlation between CSF and
serum neurofilaments revealed that NFL levels in matched CSF
and serum samples were highly correlated (Lu et al., 2015),
while the correlation between plasma and CSF levels of pNFH is
controversial (Ganesalingam et al., 2011; Li et al., 2016). CSF and
blood matrices may act differently on neurofilament homeostasis
and clearance depending on its concentrations (Lu et al., 2015).
Future studies are required to further explore the relationship
between CSF and blood levels of neurofilament and to optimize
the detection of neurofilaments in the blood as well.
This meta-analysis had some limitations. First, we only
included 10 studies, most of which had a relatively small sample
size. Thus, though no significant heterogeneity or publication
bias was found, we were unable to conduct meta-regression
to further investigate the variability between studies, and to
conclude the optimal cutoff value. Second, certain concerns
were raised during quality assessment of the included studies.
Most studies are case-control designed, which warrants well-
designed prospective cohort studies with larger sample size in
the future. Furthermore, most studies did not explicitly report
whether a consecutive or random sample of patients was enrolled,
and four studies used healthy controls, and ROC was used to
Frontiers in Aging Neuroscience | www.frontiersin.org 8 November 2016 | Volume 8 | Article 290
fnagi-08-00290 November 28, 2016 Time: 16:23 # 9
Li et al. CSF Neurofilament as Diagnostic Biomarkers in MND
determine a cutoff to give the optimum sensitivity and specificity
in all studies. All of above might lead to overestimation of
the test performance. It should also be noted that increased
neurofilament level are not specific for ALS and have been
reported in a number of other neurological diseases, including
multiple sclerosis, dementia and brain trauma (Norgren et al.,
2003; Skillback et al., 2014; Arrambide et al., 2016; Kirkcaldie
and Collins, 2016; Xu et al., 2016). An ideal study should include
other neurodegenerative disorders and ALS mimics as controls
and use a pre-specified threshold. Finally, most studies included
in the meta-analysis were from western countries, while only two
studies were from China and there is no relevant report about
other Asian population or African population. This becomes
important because ALS patients from Asia are very different and
they survive substantially longer than western patients (Nalini
et al., 2008; Liu et al., 2014).
CONCLUSION
This meta-analysis demonstrated that CSF neurofilaments
may currently serve as diagnostic biomarkers for MND.
Our data support future prospective studies of neurofilament
levels in CSF to determine its clinical utility. Standardized
procedures for obtaining and processing CSF, and an
improved understanding of how neurofilaments change
with the pathology will further strengthen the case for
neurofilaments in the diagnosis and therapeutic trials of
ALS.
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